Published in J Mol Neurosci on April 01, 2003
An aggression-specific cell type in the anterior hypothalamus of finches. Proc Natl Acad Sci U S A (2012) 0.86
VPAC receptor signaling modulates grouping behavior and social responses to contextual novelty in a gregarious finch: a role for a putative prefrontal cortex homologue. Horm Behav (2013) 0.82
Pair bond formation is impaired by VPAC receptor antagonism in the socially monogamous zebra finch. Behav Brain Res (2014) 0.80
New perspectives on vasoactive intestinal polypeptide as a widespread modulator of social behavior. Curr Opin Behav Sci (2015) 0.76
The Role of VIP in Social Behavior: Neural Hotspots for the Modulation of Affiliation, Aggression, and Parental Care. Integr Comp Biol (2016) 0.75
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol (2012) 1.64
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther (2008) 1.41
Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res (2003) 1.38
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther (2007) 1.30
NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis (2009) 1.26
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity. Proc Natl Acad Sci U S A (2003) 1.23
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol (2006) 1.14
A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem (2004) 1.12
Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem (2007) 1.12
Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem (2006) 1.08
PolyADP-ribosylation is involved in neurotrophic activity. J Neurosci (2005) 1.06
PolyADP-ribosylation is required for long-term memory formation in mammals. J Neurochem (2009) 1.03
NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke (2002) 1.01
Novel peptides prevent alcohol-induced spatial learning deficits and proinflammatory cytokine release in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol (2005) 1.00
Neuroprotective protein and carboxypeptidase E. J Mol Neurosci (2009) 0.99
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci (2010) 0.98
ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J Mol Neurosci (2008) 0.98
Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein. Brain Res Rev (2006) 0.97
2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead. J Med Chem (2007) 0.97
Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther (2004) 0.97
Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol (2004) 0.96
Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures. J Mol Neurosci (2005) 0.95
Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia. Eur Neuropsychopharmacol (2010) 0.95
NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol Dis (2013) 0.94
Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model. Neurobiol Dis (2011) 0.93
NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr Pharm Des (2007) 0.92
Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett (2004) 0.92
Cathepsins B and L differentially regulate amyloid precursor protein processing. J Pharmacol Exp Ther (2008) 0.92
NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function. Ann N Y Acad Sci (2006) 0.91
The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS One (2012) 0.90
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy. Neuropsychiatr Dis Treat (2012) 0.90
Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem (2012) 0.90
Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci (2007) 0.89
Orexins promote survival of rat cortical neurons. Neurosci Lett (2011) 0.89
The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2005) 0.88
From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division. J Mol Neurosci (2003) 0.88
Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome. Exp Neurol (2003) 0.87
NAP protects against cytochrome c release: inhibition of the initiation of apoptosis. Eur J Pharmacol (2009) 0.87
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia. Peptides (2010) 0.87
Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons. Epilepsy Res (2008) 0.87
Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. J Mol Neurosci (2009) 0.86
The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides (2003) 0.86
Tau and caspase 3 as targets for neuroprotection. Int J Alzheimers Dis (2012) 0.86
Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Regul Pept (2004) 0.86
Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des (2011) 0.86
Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer. Curr Pharm Des (2007) 0.85
Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation. J Mol Neurosci (2006) 0.85
NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther (2006) 0.85
Retinal melatonin production: role of proteasomal proteolysis in circadian and photic control of arylalkylamine N-acetyltransferase. Invest Ophthalmol Vis Sci (2002) 0.85
Learning enhancement with neuropeptides. Am J Obstet Gynecol (2006) 0.85
Complex array of cytokines released by vasoactive intestinal peptide. Neuropeptides (2003) 0.84
Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem (2007) 0.84
A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes. Life Sci (2002) 0.84
PACAP in avians: origin, occurrence, and receptors--pharmacological and functional considerations. Curr Pharm Des (2003) 0.83
NAP protects hippocampal neurons against multiple toxins. Peptides (2007) 0.83
Activation of orexin/hypocretin type 1 receptors stimulates cAMP synthesis in primary cultures of rat astrocytes. Pharmacol Rep (2011) 0.83
(N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist. J Mol Neurosci (2002) 0.83
Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling. J Mol Neurosci (2013) 0.83
The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury. Curr Alzheimer Res (2005) 0.82
The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome. Am J Obstet Gynecol (2003) 0.82
The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy. J Neurochem (2009) 0.82
The pregnant spontaneously hypertensive rat as a model of asymmetric intrauterine growth retardation and neurodevelopmental delay. Hypertens Pregnancy (2005) 0.82
Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations. J Neurosci Methods (2007) 0.81
UV-A light regulation of arylalkylamine N-acetyltransferase activity in the chick pineal gland: role of cAMP and proteasomal proteolysis. J Pineal Res (2005) 0.81
Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides (2013) 0.81
Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability. J Pept Sci (2008) 0.81
Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci (2006) 0.81
VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target. Peptides (2006) 0.81
The effects of vascular intrauterine growth retardation on cortical astrocytes. J Matern Fetal Neonatal Med (2010) 0.81
New horizons in schizophrenia treatment: autophagy protection is coupled with behavioral improvements in a mouse model of schizophrenia. Autophagy (2014) 0.81
NAP protects against cyanide-related microtubule destruction. J Neural Transm (Vienna) (2009) 0.80
Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina. Peptides (2005) 0.80
Looking for novel ways to treat the hallmarks of Alzheimer's disease. Expert Opin Investig Drugs (2007) 0.80
A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model. J Mol Neurosci (2008) 0.79
D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy. J Mol Neurosci (2012) 0.79
High-throughput siRNA-based functional target validation. J Biomol Screen (2004) 0.79
Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus. Neurosci Lett (2005) 0.79
Vasoactive intestinal peptide regulation of nerve growth factor in the embryonic mouse. Peptides (2002) 0.79
Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. J Mol Neurosci (2007) 0.79
A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis. J Mol Neurosci (2002) 0.78
3R tau expression modifies behavior in transgenic mice. J Neurosci Res (2010) 0.78
[Influence of the shift work on circadian-rhythms compare survey on health service employees and policemen]. Przegl Lek (2012) 0.78
Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. Neuroreport (2003) 0.78
Vasoactive intestinal peptide mRNA and immunoreactivity are decreased in fetal alcohol syndrome model. Regul Pept (2002) 0.78
Assessing activity onset time and efficacy for clinically effective antidepressant and antimanic drugs in animal models based on dominant-submissive relationships. Neurosci Biobehav Rev (2007) 0.78
[Health consequences of shift work]. Przegl Lek (2011) 0.77
PACAP38 and PACAP6-38 exert cytotoxic activity against human retinoblastoma Y79 cells. J Mol Neurosci (2014) 0.77
Rapid desensitization of receptors for pituitary adenylate cyclase-activating polypeptide (PACAP) in chick cerebral cortex. Pol J Pharmacol (2003) 0.77
NAP accelerates the performance of normal rats in the water maze. J Mol Neurosci (2002) 0.77
VIP and PACAP: novel approaches to brain functions and neuroprotection. Curr Pharm Des (2011) 0.77